VolitionRx Invests in Laboratory Automation System to Increase Throughput Capacity for Large Clinical Trials

NAMUR, Belgium, Aug. 13, 2014 /PRNewswire/ -- VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced it has installed a Tecan EVO200 automated liquid handling system in its Namur, Belgium laboratory. The Tecan EVO200 is a robot that will significantly accelerate VolitionRx's large scale clinical studies by increasing the throughput and rate of blood sample analysis by up to five times that of the current manual methods. Initially the robot will be used in a stand-alone mode but Volition is in the process of establishing a Laboratory Information Management System (LIMS) which will integrate the robot into a wider laboratory automation system. This will provide a seamless workflow incorporating blood sample recognition, testing, data capture, and quality control as part of a quality management system.

VolitionRx also recently outsourced large-scale production of their NuQ® kits to complement the increased sample processing capabilities the EVO200 system brings. Outsourced kit production and implementation of the quality system will be overseen by newly appointed Chief Operations Officer, Gaetan Michel, who joined the company on 1^st July. These are key milestones in moving towards European CE market approval and the ramp up for the release of our kits into the clinical market.

Installation of the robot is particularly significant as the company today announced an increase of 3,000 (from 11,000 to 14,000) in the number of prospective blood samples to be included in its on-going colorectal cancer clinical trial, which is jointly sponsored by VolitionRx and the University of Copenhagen. The study is designed to evaluate the validity of VolitionRx's proprietary NuQ® panel as a first-step screening tool for colorectal cancer and has been expanded by 42% since it initially commenced. The additional blood samples are being collected by Professor Hans Jorgen Nielsen, Professor of Surgical Oncology at the Department of Surgical Gastroenterology at Hvidovre Hospital, part of the University of Copenhagen, and collaborators at seven additional Danish hospital departments.

Speaking about today's announcements, Cameron Reynolds, CEO of VolitionRx, commented, "This is an exciting time for Volition with lots of positive change as we move towards regulatory approval and clinical launch of our products. The automated sample testing technology we have invested in will speed up our workflow and the extension to our trial with Hvidovre Hospital will give us the opportunity to analyse further data in relation to colonoscopy findings. The next key milestone will be the release of the first data from our pivotal Danish trials at the Aegis Capital Corp. 2014 Healthcare & Technology conference, to be held 10^th September to 13^th in Las Vegas, NV."

Other clinical trials assessing the effectiveness of Volition's assays include:

• A 4,000 patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany
• A 250 patient study into colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium

-Ends-

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx's website (www.volitionrx.com) or connect with us via Twitter, LinkedIn or Facebook.

Safe Harbor Statement

Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.

For more information please contact:

Charlotte Reynolds, VolitionRx
Telephone: +44 (0) 795 217 7498
Email: [email protected]

Ann-Marie Gannon, Racepoint Global
Phone: +44 (0) 208 811 2124
Email: [email protected]

SOURCE VolitionRx Ltd

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED